Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Financial Results
QuoteReporter
Bioceres Crop Solutions (BIOX) Q3 2026: Revenue Decline, Net Loss Worsens — Disappointing
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported total revenues of $39.4 million for the fiscal third quarter ended March 31, 2026, reflecting a significant decline of 23% year-over-year from $51.1 million. This disappointing performance is primarily attributed to softer demand and competitive pressures in the Crop Protection segment, alongside the ongoing transition in Seeds.
The quarter was disappointing for shareholders, primarily due to the substantial net loss of $13.4 million, compared to a net profit of $2.3 million in the same quarter last year. This stark contrast highlights the challenges the company is facing as it navigates through a period of operational refocusing and market headwinds.
Key Financial Metrics
- Total Revenue: $39.4 million (down 23% YoY from $51.1 million)
- Gross Profit: $12.7 million (down 30% YoY from $18.1 million)
- Gross Margin: 32% (down from 35% YoY)
- Net Loss: $13.4 million (compared to a net profit of $2.3 million in Q3 2025)
- Adjusted EBITDA: $(0.6) million (down from $9.1 million YoY)
- SG&A Expenses: $16.1 million (down 16% YoY from $19.2 million)
- Cash and Cash Equivalents: $14.4 million as of March 31, 2026
- Total Debt: $227.8 million
Segment Performance
- Crop Protection: Revenue decreased to $24.6 million, an 18% decline YoY, driven by lower adjuvant sales and reduced third-party product sales.
- Seed and Integrated Products: Revenue plummeted to $3.2 million, a staggering 71% drop YoY, primarily due to lower seed and grain sales.
- Crop Nutrition: This segment saw a 15% increase in revenue to $11.6 million, driven by growth in microbeaded fertilizers.
Operational Highlights
The company has been actively managing its costs, with SG&A expenses declining by 16% year-over-year. This reflects ongoing organizational streamlining and cost management initiatives. However, the overall gross profit and margins have suffered due to lower revenues and a non-recurring obsolescence adjustment in inoculants.
The net loss of $13.4 million was exacerbated by the absence of approximately $7.7 million in non-cash income from the previous year, which was associated with the reorganization in Seeds. Additionally, the company incurred higher financial expenses, leading to a total financial result of $(9.7) million, compared to $(5.6) million in the prior year.
Cash and Debt Position
As of March 31, 2026, Bioceres reported cash and cash equivalents of $14.4 million, with total debt standing at $227.8 million. The company continues to face challenges related to its debt management, particularly following the foreclosure auction of its Pro Farm Group business earlier this year.
Future Outlook
Looking ahead, the most critical catalyst to watch for Bioceres is the ongoing strategic review of its operations and the potential for improved governance and internal processes. The company is focused on stabilizing its core operations and enhancing its capital allocation strategies to create long-term value.
In summary, while the company is making strides in cost management and operational efficiency, the significant revenue decline and net loss indicate a challenging environment ahead. Shareholders will be keenly watching how Bioceres navigates these hurdles in the upcoming quarters.
| Three-month period ended 03/31/2026 | Three-month period ended 03/31/2025 | |
|---|---|---|
| Revenues from contracts with customers | 38.2 | 50.1 |
| Initial recognition and changes in the fair value of biological assets at the point of harvest | 1.2 | 1.0 |
| Cost of sales | (26.7) | (33.0) |
| Gross profit | 12.7 | 18.1 |
| % Gross profit | 32% | 35% |
| Operating expenses | (18.0) | (21.3) |
| Share of profit of JV | 0.3 | (0.9) |
| Change in net realizable value of agricultural products | (0.2) | (0.2) |
| Other income or expenses, net | (2.5) | 8.8 |
| Operating profit | (7.8) | 4.3 |
| Financial result | (9.7) | (5.6) |
| Profit/(loss) before income tax | (17.5) | (1.2) |
| Income tax | 4.0 | 3.6 |
| Profit/(loss) for the period from continuing operations | (13.4) | 2.3 |
| Loss for the period from discontinued operations | - | (3.9) |
| Other comprehensive profit/loss | 0.3 | (0.8) |
| Total comprehensive profit/(loss) | (13.7) | (2.4) |
| Profit/(loss) for the period of continuing operations attributable to | ||
| Equity holders of the parent | (12.4) | 2.6 |
| Non-controlling interests | (1.1) | (0.3) |
| (13.4) | 2.3 | |
| Weighted average number of shares | ||
| Basic | 63.6 | 62.8 |
| Diluted | 63.6 | 62.8 |
| ASSETS | 31/03/2026 | 30/06/2025 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | 14.4 | 32.7 |
| Other financial assets | 0.5 | 2.0 |
| Trade receivables | 136.7 | 165.9 |
| Other receivables | 13.1 | 15.9 |
| Recoverable income tax | 1.4 | 1.9 |
| Inventories | 48.4 | 87.6 |
| Biological assets | 4.4 | 2.4 |
| Assets subject to foreclosure | 42.4 | - |
| Total current assets | 261.2 | 308.3 |
| NON-CURRENT ASSETS | ||
| Other financial assets | 0.0 | 0.0 |
| Trade receivables | 1.3 | 2.5 |
| Other receivables | 28.8 | 23.7 |
| Recoverable income tax | 0.0 | 0.0 |
| Deferred tax assets | 8.3 |
DisclaimerThe content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information. Related Articles Trending Stocks Nasdaq 100 Bull & Bear Radar — September 15, 2026A daily technical sweep of 100 Nasdaq 100 constituents ranked by session performance, enriched with RSI, MA20/MA50/MA200 trend signals, Bloomberg-style… QuoteReporter 6 minSep 15, 2026 Trending Stocks S&P 500 Bull & Bear Radar — September 15, 2026A daily technical sweep of 492 S&P 500 constituents ranked by session performance, enriched with RSI, MA20/MA50/MA200 trend signals, Bloomberg-style… QuoteReporter 6 minSep 15, 2026  Trending Stocks Vera Bradley (VRA) VQ2 2027 Financial Results SummaryVera Bradley (VRA) Q2 2027: Revenue Growth Continues — Positive Momentum Vera Bradley, Inc. (Nasdaq: VRA) reported its second quarter fiscal year 2027 results, showcasing a modest yet significant improvement in performance. The company achieved consolidated net revenues of $71.6 million, reflecting... QuoteReporter 3 minSep 15, 2026 |